EC extends J&J/Pfizer look
This article was originally published in The Tan Sheet
Executive Summary
The European Commission extends its antitrust review of Johnson & Johnson's planned $16.6 bil. acquisition of Pfizer's consumer healthcare unit to consider remedies proposed by the companies to resolve potential competition problems previously identified by the commission. EC planned to rule on the deal Nov. 27, but moved the deadline to Dec. 11 (1"The Tan Sheet," Oct. 30, 2006, In Brief). An EC spokesperson on Nov. 22 said the agency extends inquiries by 10 working days when companies being reviewed have offered remedies to competition concerns cited in an investigation. To facilitate completing its acquisition of Pfizer's OTC brands, including Nicorette and Sudafed, J&J already agreed to sell its OTC Zantac heartburn medication to Boehringer for $509 mil. (2"The Tan Sheet" Oct. 16, 2006, p. 9)...
You may also be interested in...
J&J, Pfizer Satisfy FTC Conditions To Clear Deal; EC Signs Off
Johnson & Johnson and Pfizer's divestiture of the Zantac, Cortizone, Unisom and Balmex brands satisfies the Federal Trade Commission's anticompetitive complaint about J&J's acquisition of Pfizer's consumer healthcare business
EC eyes J&J-Pfizer
The European Commission says it will decide by Nov. 27 whether to sign off on Johnson & Johnson's proposed acquisition of Pfizer Consumer Healthcare or to open a full-scale investigation in a process that could last three months. The EC's Competition Directorate will accept comments on the proposed deal until 10 calendar days from the date it announced its preliminary review, Oct. 26. J&J proposes paying $16.6 bil. for Pfizer's OTC brands, including Nicorette and Sudafed (1"The Tan Sheet" July 3, 2006, p. 3). To facilitate the deal's completion, J&J already has agreed to sell its OTC Zantac heartburn medication to Boehringer for $509 mil. (2"The Tan Sheet" Oct. 16, 2006, p. 9)...
Boehringer Hits Above The Belt With Zantac Purchase
Boehringer Ingelheim looks to expand its therapeutic territory up the GI tract with a $509.5 mil. purchase of U.S. rights to the acid reducer Zantac (ranitidine) from Johnson & Johnson and the Pfizer Consumer Healthcare business